HMPL-760

Phase 3Small molecule

HMPL-760 is one of 8 small molecule programs targeting Relapsed/Refractory Diffuse Large B-cell Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed/refractory Diffuse Large B-Cell LymphomaRecruiting

Relapsed/refractory Diffuse Large B-Cell LymphomaPhase 3

Recruiting

Competition

Competitive Landscape

7 competitors in Relapsed/refractory Diffuse Large B-Cell Lymphoma

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

2 2

COLUMVI

Roche

Phase 2

1 3

R-Gemox

HHutchmed

Phase 3

1 4

HMPL-760

HHutchmed

Phase 3

1 5

Gemzar

Johnson & Johnson

Preclinical

1 6

Decadron

AAspen Global Incorporated

Preclinical

1 7

Xpovio

KKaryopharm Therapeutics Inc

Preclinical

1 8

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Relapsed/refractory

NCT06601504

Q4 2028

Phase 3Recruiting

Relapsed/refractory Diffuse Large B-Cell Lymphoma

NCT07409428

Clinical

Trials by Indication[1]

Relapsed/Refractory1 trial

Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

Active, not recruiting·HHutchmed·Phase 2·NCT06601504·61 enrolled

CLL/SLL1 trial

HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL

Withdrawn·HHutchmed·Phase 1·NCT05176691

Lymphoma1 trial

HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Completed·HHutchmed·Phase 1·NCT05190068·89 enrolled

Relapsed/Refractory Diffuse Large B-cell Lymphoma1 trial

A Phase III Randomized, Double-Blind, Positive Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Recruiting·HHutchmed·Phase 3·NCT07409428·240 enrolled

Unspecified1 trial

An Open-Label, Randomized, Four-Period, Six-Sequence Phase I Study to Evaluate the Effect of Food and Proton Pump Inhibitor Rabeprazole on the Pharmacokinetics of HMPL-760 Capsules in Healthy Participants

Completed·HHutchmed·Phase 1·NCT07643272·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for HMPL-760. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HMPL-760 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HMPL-760. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hutchmed company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHutchmed

HMPL-760

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2028

Trials by Indication[1]

Relapsed/Refractory1 trial

CLL/SLL1 trial

Lymphoma1 trial

Relapsed/Refractory Diffuse Large B-cell Lymphoma1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News